Patent details
301054
Product Name:
Saxagliptin and dapagliflozin
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
301054
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2139494
Status:
Refused Art. 10 of the EC Regulations
Application number:
301054
Procedural language:
Dutch
First Applicant Residence Country:
Sweden (SE)
Marketing Authorization
Marketing Authorization Number:
EU/1/16/1108
Marketing Authorization Type:
EEA
Marketing Authorization Date:
19/07/2016
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
08/07/2020
First Marketing Authorization date:
19/07/2016
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
08/07/2020
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
15/12/2021
Applicant/holder
From:
08/07/2020
Name:
AstraZeneca AB
Address:
-, 151 85 SÖDERTÄLJE, Sweden (SE)
Agent
Name:
ir. J.C. Volmer c.s.
From:
08/07/2020
Address:
Exter Polak & Charlouis B.V.
Postbus 3241, 2280 GE, Rijswijk, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
51/21
Publication date:
22/12/2021
Description:
Lapse or annulment
2
Bulletin Heading:
SPC
Journal edition number:
29/20
Publication date:
14/08/2020
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
15/12/2021
Outgoing Correspondence
Decision refusal
5
PDF
/0/9/3/5/7/0800575390/docs/301054_11_451079l527a.pdf
18/10/2021
Incoming Correspondence Paper
Accompanying letter incoming document
8
PDF
/0/9/3/5/7/0800575390/docs/301054_2_incomingcorrespondencepaper20211019100546233.pdf
18/10/2021
SPC Documents
Annex SPC
3
PDF
/0/9/3/5/7/0800575390/docs/301054_6_supplprotectioncertificate20211019100627090.pdf
20/07/2021
Outgoing Correspondence
Letter to applicant
2
PDF
/0/9/3/5/7/0800575390/docs/301054_9_424517l173.pdf
08/07/2020
Outgoing Correspondence
Confirmation receipt request
1
PDF
/0/9/3/5/7/0800575390/docs/301054_0_353129l174.pdf
08/07/2020
SPC Documents
Accompanying letter SPC
4
PDF
/0/9/3/5/7/0800575390/docs/301054_1_supplprotectioncertificate20200708011300502.pdf
08/07/2020
SPC Documents
Annex SPC
2
PDF
/0/9/3/5/7/0800575390/docs/301054_3_supplprotectioncertificate20200708011300748.pdf
08/07/2020
SPC Documents
Summary of the characteristics of the product
25
PDF
/0/9/3/5/7/0800575390/docs/301054_4_supplprotectioncertificate20200708011300819.pdf
08/07/2020
SPC Documents
Annex SPC
2
PDF
/0/9/3/5/7/0800575390/docs/301054_5_supplprotectioncertificate20200708011300900.pdf
08/07/2020
SPC Documents
Annex SPC
16
PDF
/0/9/3/5/7/0800575390/docs/301054_7_supplprotectioncertificate20200708011300957.pdf
08/07/2020
SPC Documents
Marketing Authorization SPC
3
PDF
/0/9/3/5/7/0800575390/docs/301054_8_supplprotectioncertificate20200708011300679.pdf
08/07/2020
Application Form
First filed application form
2
PDF
/0/9/3/5/7/0800575390/docs/301054_10_applicationform20200708011300553.pdf